Oral semaglutide was superior to placebo in reducing HbA1c and body weight when added to insulin ± metformin in patients with type 2 diabetes. The safety profile was consistent with other glucagon-like peptide-1 receptor agonists (Diabetes Care)
Diabetes News
Tag: insulin
Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes
Low-dose SGLTi profile was the favored adjunct-to-insulin therapy by persons with T1D (Diabetes Care)
Post-Basal Insulin Intensification and Healthcare Resource Use in Type 2 Diabetes: A Web-Based Physician Survey in the United States and United Kingdom
Less complex regimens for intensification following basal insulin may help reduce the time and healthcare resources required for intensification and address some of the challenges T2D patients face when intensifying to basal–bolus or basal with GLP-1 (Diabetes Therapy)
Investigating optimal β‐cell‐preserving treatment in latent autoimmune diabetes in adults: Results from a 21‐month randomized trial
β‐cell function after intervention was similar in patients with insulin‐ and sitagliptin‐treated LADA, regardless of the strength of autoimmunity. Further, participants with low levels of GAD antibodies did not experience progressive deterioration of β‐cell function over a 21‐month period. Taken together, these findings could be useful for clinicians’ choices of treatment in people with LADA (Diabetes, Obesity and Metabolism)
A randomized trial comparing the efficacy and safety of treating patients with very elevated hba1c levels with basal‐bolus insulin or a glp‐1 receptor agonist plus basal insulin
In patients with HbA1c≥10% treatment with GLP1RA plus basal insulin, compared with basal‐bolus insulin, resulted in better glycemic control and weight, lower insulin dosage and hypoglycemia, and improved quality of life. This treatment strategy is an effective and safe alternative to basal‐bolus insulin regimen (Diabetes, Obesity and Metabolism)
Use of sensor‐integrated pump therapy to reduce hypoglycaemia in people with Type 1 diabetes: a real‐world study in the UK
Real‐world UK data show that increasing automation of insulin suspension reduces hypoglycaemia exposure in people with Type 1 diabetes (Diabetic Medicine)
Glycaemic benefit of iGlarLixi in insulin‐naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan‐O randomized trial
These results suggest that iGlarLixi achieves superior glycaemic control compared with iGlar or Lixi alone in T2DM patients with HbA1c ≥9% or those inadequately controlled on two OADs (Diabetes, Obesity and Metabolism)
Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation
There is an incremental risk of ischemic stroke and MI from non-diabetics to non-insulin diabetics with the highest risk in insulin users. Protective effect of anticoagulation is attenuated with insulin use (American Heart Journal)
Implementation of Basal–Bolus Therapy in Type 2 Diabetes
Bolus insulin delivered by patch and pen using an algorithm-based weekly insulin dose titration significantly improved HbA1c in adults with type 2 diabetes, with improved subject and health care provider experience and preference for the patch (Diabetes Technology and Therapeutics)
Interventions to improve insulin prescribing practice for people with diabetes in hospital: a systematic review
Implementing strategies that are sensitive to local context and designed to increase adherence to insulin prescribing guidelines are associated with a reduction in prescribing errors. Future implementation should build on effective approaches including multifaceted interventions involving multiple stakeholders at various institutional levels (Diabetic Medicine)
Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials
In type 1 diabetes, sotagliflozin improves glycaemic and non-glycaemic outcomes and reduces hypoglycaemia rate and severe hypoglycaemia. The risk of diabetic ketoacidosis could be minimised by appropriate patient selection and down-titration of the basal insulin dose (BMJ)
Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes
When initiating insulin glargine therapy, continuation of sitagliptin, compared with discontinuation, resulted in a clinically meaningful greater reduction in HbA1c without an increase in hypoglycaemia (Diabetes, Obesity and Metabolism)
Safer insulin prescribing
This document summarises the evidence base on safer insulin prescribing. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance
Longitudinal Changes in HbA1c following Treatment Intensification after Inadequate Response to Two Oral Antidiabetic Agents in Patients with Type 2 Diabetes
In patients with T2DM, intensification following A1c ≥7.0% on 2OADs was associated with a significant improvement in glycemic control. Patients intensified with insulin had a higher baseline A1c but greater A1c reduction than those intensified with a non‐insulin agent. However, A1c remained above 8.0% overall (Diabetes, Obesity and Metabolism)
Association Between Triglyceride Level and Glycemic Control Among Insulin-Treated Patients With Type 2 Diabetes
Elevated triglyceride levels were strongly associated with inadequate glycemic control; thus, suppressing triglyceride levels may attain more optimal glycemic control in patients with type 2 diabetes (Journal of Clinical Endocrinology & Metabolism)
Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial
The combination of automated insulin titration guidance with support from health-care professionals offers superior glycaemic control compared with support from health-care professionals alone (The Lancet)
Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial
I338 can safely improve glycaemic control in insulin-naive patients with type 2 diabetes with no evidence of a difference compared with insulin glargine, a widely used subcutaneously administered basal insulin (The Lancet Diabetes & Endocrinology)
Perceptions of insulin therapy in people with type 2 diabetes and physicians: a cross-sectional survey conducted in France
Most people with T2D reported that transitioning to insulin therapy was less difficult than they had feared. People with T2D and physicians exhibited differing perceptions regarding the transition (Patient Preference and Adherence)
The effect of short-term intensive insulin therapy on circulating T cell subpopulations in patients with newly diagnosed type 2 diabetes mellitus
Short-term intensive insulin therapy could modulate circulating T cell subpopulations in patients with T2DM, which might alleviate inflammatory responses caused by hyperglycemia
Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study
During DCCT/EDIC, higher insulin doses were associated with adverse trends in several cardiometabolic risk factors, even after multivariable adjustment, but not with incident CVD outcomes (Diabetes Care)
- 1
- 2
- 3
- …
- 10
- Next Page »
Glycosmedia is also available as an App: